市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Innate Pharma S.A. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 1.7 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | -2.5 |
| 相对估值 | NA |
| 财务健康 | -0.5 |
| 宏观环境 | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | -0.43 |
|
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 机构持股比例 | 0.24% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Lion Point Capital, Lp | 30 Jun 2026 | 81,151 |
| Smartharvest Portfolios, Llc | 30 Sep 2026 | 20,868 |
| Rhumbline Advisers | 30 Jun 2026 | 4,719 |
| Farther Finance Advisors, Llc | 30 Sep 2026 | 10 |
| Gamma Investing Llc | 30 Sep 2026 | 9 |
投资组合